Latest News “Nature Biotechnology: COVID-19 long haulers” Click here. “Ampio gets promising data on drug that could be used to treat COVID” Click here. Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business UpdateDate: July 14, 2021 | READ MORE > Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory DistressDate: June 25, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® IndexDate: June 18, 2021 | READ MORE > Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAKDate: June 17, 2021 | READ MORE > Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to IndiaDate: June 15, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Summer Healthcare SymposiumDate: June 14, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and ExpoDate: June 14, 2021 | READ MORE > Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International CongressDate: May 21, 2021 | READ MORE > Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)Date: May 10, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business UpdateDate: May 5, 2021 | READ MORE > Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%Date: April 27, 2021 | READ MORE > Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19Date: April 27, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business UpdateDate: April 21, 2021 | READ MORE > Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse EffectsDate: April 19, 2021 | READ MORE > Ampio Pharmaceuticals’ Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus NephritisDate: April 6, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International CongressDate: March 29, 2021 | READ MORE > Ampio Pharmaceuticals to Present at Benzinga Biotech Small Cap ConferenceDate: March 19, 2021 | READ MORE > Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory DistressDate: March 16, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021Date: March 10, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business UpdateDate: March 3, 2021 | READ MORE >
